Neuphoria Therapeutics Inc (NEUP) - 股价大幅下跌67.18%至5.05美元，主要原因是其用于治疗社交焦虑障碍的BNC210药物AFFIRM-1三期临床试验未能达到主要和次要终点 [1] - 公司计划对其产品组合和业务运营进行战略评估 [1] AlphaVest Acquisition Corp (ATMVU) - 作为特殊目的收购公司，其股价下跌41.05%至12.97美元 [2] - 股价波动可能与公司和原生计算机视觉AI平台领导者AMC Corporation达成的合并协议有关，此类SPAC的投机性质常导致股价波动 [2] Cycurion, Inc (CYCU) - 这家网络安全公司股价下跌34.51%至0.16美元 [3] - 公司收到纳斯达克的退市决定函，将启动程序将其普通股从纳斯达克全球市场退市，此举严重影响投资者信心 [3] SMX Public Limited Company (SMX) - 专注于追踪和溯源技术的公司股价下跌32.03%至0.78美元 [4] - 市场表现可能反映了行业趋势或尚未详细披露的运营更新，信息缺乏导致投资者对其未来前景不确定 [4] American Rebel Holdings, Inc (AREB) - 股价下跌29.91%至1.31美元 [5] - 尽管公司已确保其American Rebel Light啤酒在东南部杂货商全部416个门店获得分销位置，实现了重要的区域扩张，但股价下跌可能反映了影响消费周期性板块的更广泛经济因素 [5] 市场动态总结 - 近期市场波动凸显了股票市场的多变特性，公司特定新闻、行业趋势和广泛的经济条件均可显著影响股价 [6] - Neuphoria Therapeutics因三期试验结果失败导致股价暴跌，AlphaVest Acquisition在宣布与AMC Corporation合并后股价大幅下跌，Cycurion面临从纳斯达克退市严重冲击其股价 [7]

AFFIRM-1 trial did not meet primary endpoint or secondary endpoints Company to conduct strategic review of portfolio and business operations BURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced that the AFFIRM-1 Phase 3 trial of BNC210 for the acute treatment of social anxiety disorder (SAD) did not meet its primary ...

BURLINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced an upcoming presentation at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting. Presentation details: Title: Pharmacokinetic/Pharmacodynamic Analysis of the BNC210 Attune Phase 2b Dataset Enables Dose Selection for Planned Phase 3 PTSD St ...

Cash runway into Q3 2026AFFIRM-1 Phase 3 clinical trial of BNC-210 in social anxiety disorder on track for topline readout in Q3 2025α7 nicotinic acetylcholine receptor PAM MK-1167 partnered with Merck and in Phase 2 clinical trial in Alzheimer’s BURLINGTON, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today provides business updates for ...